Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
← catalyst calendarNCT06980116 · readout ≤ 680 d
Sponsored by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. (industry) · RXRX — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
85estimated
Sites
17
Countries
Georgia, Greece, Moldova +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-31 | actual | When the study began enrolling |
| Primary completion | Jun 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Relapsed or Refractory B-cell Malignancies
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Follicular Lymphoma (FL)
- Marginal Zone Lymphoma (MZL)
- Mantle Cell Lymphoma (MCL)
- Diffuse-large B-cell Lymphoma (DLBCL)
- Waldenstrom's Macroglobulinemia (WM)
Intervention
- Drug: EXS73565
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Treatment-emergent Adverse Events (TEAEs)
measured Up to 282 days
Number of Participants With Dose-limiting toxicities (DLTs)
measured Up to 28 days
Permalink · RXRX's whole pipeline · Catalyst calendar · Every registered study · What changed